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The major histocompatibility complex (MHC) class I region in mammals contains both classical and non-classical MHC class I genes.
Classical MHC class I molecules present antigenic peptides to cytotoxic T lymphocytes, whereas non-classical MHC class I molecules have a
variety of functions. Both classical and non-classical MHC molecules interact with natural killer cell receptors and may under some circumstances
prevent cell death by natural killer cytotoxicity. The E5 oncoprotein of BPV-4 down-regulates the expression of classical MHC class I on the cell
surface and retains the complex in the Golgi apparatus. The inhibition of classical MHC class I to the cell surface results from both the impaired
acidification of the Golgi, due to the interaction of E5 with subunit c of the H+ V-ATPase, and to the physical binding of E5 to the heavy chain of
MHC class I. Despite the profound effect of E5 on classical MHC class I, E5 does not retain a non-classical MHC class I in the Golgi, does not
inhibit its transport to the cell surface and does not bind its heavy chain. We conclude that, as is the case for HPV-16 E5, BPV-4 E5 does not down-
regulate certain non-classical MHC class I, potentially providing a mechanism for the escape of the infected cell from attack by both cytotoxic T
lymphocytes and NK cells.
© 2006 Elsevier B.V. All rights reserved.Keywords: BPV; E5; Classical MHC class I; Non-classical MHC class I; E5-MHC class I interaction; MHC class I down-regulationIntroduction
Viruses have to evade the innate and adaptive host immune
response to establish infection and persist at least until new
progeny virus is released. Many viruses have developed the
ability of down-regulating the major histocompatibility com-
plex (MHC) class I (Piguet, 2005), thus avoiding lysis by
cytotoxic T lymphocytes (CTL; effector cells capable of
recognizing and destroying transformed or infected cells),
while not interfering with expression of some non-classical
MHC class I genes. Some non-classical MHC class I molecules,
in common with classical class I molecules, engage both
inhibitory and activating receptors of natural killer (NK) cells,
components of the innate immune response, which may⁎ Corresponding author. Fax: +44 141 330 5602.
E-mail address: s.campo@vet.gla.ac.uk (M.S. Campo).
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doi:10.1016/j.virol.2006.05.031recognize and destroy cells with low levels of MHC class I.
The absence of down-regulation of some non-classical MHC
class I genes, or their up-regulation, by virus may result in the
failure of NK cells to kill virus-infected cells and allows virus to
escape both CTL and NK killing (Cohen et al., 1999; Tomasec
et al., 2000; Wang et al., 2002).
Papillomaviruses (PV) are small oncogenic viruses that
infect mucosal and cutaneous epithelia causing benign
hyperproliferative lesions (papillomas, warts, condylomas).
Infection by PV is under immunological control, this is
demonstrated by epidemiological studies showing that, in both
human and animal hosts with genetic, iatrogenic or acquired
cell-mediated immune deficiencies, PV lesions show increased
persistence and enhanced neoplastic progression (see O'Brien
and Campo, 2002 for review). However, even in immunocom-
petent individuals, despite expressing abundant viral protein,
PV persist for a significant period of time, usually spanning
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immune system. This lack of recognition suggests that the host
immune system is unaware of, and/or disabled by, PV infection.
Indeed, the ability of PV to persist has been attributed to several
causes: the nature of the virus life cycle, which takes place
wholly in the epithelium and therefore prevents high levels of
the viral proteins having access to the immune cells; the entry of
PV to a latent state with very low levels of expression of viral
antigens; and, as demonstrated recently, the ability of the virus
to directly subvert and evade the host immune response (Frazer
et al., 1999; O'Brien and Campo, 2002; Tindle, 2002). It is
likely that the contribution of each of these factors results in a
delay or prevention of resolution of infection.
It is becoming clear that the oncoproteins of PV can
interfere with the host immunosurveillance and response
(O'Brien and Campo, 2002). We have shown that the E5
oncoprotein of both BPV and HPV inhibits the transport of
MHC class I to the cell surface and retains it in the Golgi
apparatus (Araibi et al., 2004; Ashrafi et al., 2002, 2005;
Marchetti et al., 2002). Additionally, we have shown that
BPV-4 E5 interacts physically with bovine MHC class I
heavy chain (HC) and that both this interaction and the down-
regulation of the complex require the C-terminus domain of
E5 (Marchetti et al., 2006).
Although effectively down-regulating surface classical
MHC class I, HPV-16 E5 does not interfere with the
transport of non-classical MHC class I to the cell surface
(Ashrafi et al., 2005). It is not known if this is the case also
for BPV E5.
Recently, nine putative non-classical class I sequences
(N*50001-N*50501, see http://www.ebi.ac.uk/ipd/mhc/bola/)
have been identified in cattle cDNAs, most of which have not
yet been functionally characterized. N*50001 (GenBank
accession: AY188807) was first identified in 1995 when it
was termed HD59 (Ellis et al., 1996) and subsequently was
mapped to a region of the cattle MHC containing several
classical class I genes (Di Palma et al., 2002). N*50001
encodes an HC with a truncated cytoplasmic domain (8 rather
than 28 amino acids) and in this sense resembles human
HLA-G (Geraghty et al., 1987).
Here, we show that BPV-4 E5 cannot down-regulate
expression of N*50001 MHC class I complex or interact with
N*50001 HC, suggesting that, like other viruses, BPV is
potentially capable of evading CTL and NK killing of infected
cells.
Results
We have shown that BPV-4 E5 binds to bovine class I HC
and have mapped the HC-interacting domain of E5 to its C-
terminus end (Marchetti et al., 2006). We have also shown that
HPV-16 E5 down-regulates classical HLA I (MHC class I) but
not non-classical HLA-E (Ashrafi et al., 2005). To determine
whether BPV-4 E5, like HPV-16 E5, is incapable of down-
regulating certain non-classical MHC genes, we took advantage
of a recently described gene in the bovine MHC class I cluster,
N*50001 (Di Palma et al., 2002).N*50001 has an early stop codon in the sequence encoding
the intracytoplasmic domain (producing a C-terminal truncated
HC), has a number of base pairs substitutions leading to unusual
amino acids (see Fig. 1), has a large deletion in the 3′UTR and
significant differences in the promoter region compared to
classical class I genes (data not shown). It is prone to alternative
splicing, in common with some other non-classical class I
genes, and the isoform most often found was used in this study
(Fig. 1). This isoform contains a small section of intron 4
resulting in 4 additional amino acids at the end of the alpha 3
domain. N*50001 is recognized by mAb IL-A88, an mAb that
recognizes a monomorphic determinant on all bovine classical
MHC class I molecules (Toye et al., 1990) (Fig. 4). mAb IL-
A88 was used throughout the present work.
Generation of mouse P815 cells expressing bovine MHC
class I
It is not possible to analyze the expression or the function
of N*50001 in bovine cells (in vivo) because there is no
specific antibody for its protein. To investigate the properties
of this gene, its cDNA was introduced into the mouse cell line
P815, giving rise to P815-N*50001 cells. P815-N*01301 cells
were generated in a similar way. There was no need to co-
transfect the bovine β2 microglobulin (β2m) gene with the
bovine MHC HC genes into P815 cells because the bovine
class I HC associates with mouse β2m, and when the complex
reaches the cell surface, it rapidly exchanges mouse β2m with
bovine β2m provided by the fetal calf serum in the culture
medium (Ellis et al., 2005). Both N*01301 and N*50001 are
expressed in P815 cells and transported to the cell surface (see
below and Fig. 3).
Stable introduction and expression of BPV-4 E5 into
P815-N*01301 and P815-N*50001 cells
Any interaction between E5 and N*50001 cannot be studied
in bovine cells, such as our well-characterized PalF cell lines as
there are not specific antibodies for this HC and the mAb IL-
A88, which recognizes N*50001, recognizes all other MHC
class I HC. The P815-N*01301 and P815-N*50001 cells gave
us an opportunity to analyze the functional relationship between
E5 and N*50001 independently from the interaction between
E5 and N*01301. We introduced E5 into these cells, either
expressed from the murine MuLV transcriptional promoter in
pZipneo (pz4E5) or expressed from the IE promoter of HCMV
in pcDNA3 (pc4E5). The corresponding empty vectors were
also introduced into the P815-N*01301 and P815-N*50001
cells as controls. We generated the following cell lines: P815-
N*01301-pz4E5, P815-N*01301-pc4E5, P815-N*01301-pZip,
P815-N*01301-pcDNA, P815-N*50001-pz4E5, P815-
N*50001-pc4E5, P815-N*50001-pZip and P815-N*50001-
pcDNA.
We determined the expression of E5 by quantitative RT-
PCR. There was little or no difference in E5 expression whether
expressed from the MLV LTR or the CMV IE promoter, either
in P815-N*01301 or in P815-N*50001 cells (Fig. 2).
Fig. 1. Alignment of the predicted amino acid sequences of N*01301 and N*50001 (splice variant). Dots indicate identity, *Indicates stop codon. Divergent amino
acids (bold) are seen only in N*50001 (or other cattle non-classical class I alleles) and are not seen in cattle classical class I alleles (www.ebi.ac.uk/ipd/mhc/bola/). Four
additional amino acids at the end of the alpha 3 domain of N*50001 are the result of incorrect splicing of intron 4.
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BPV-4 E5
The expression of N*01301 or N*50001 was analyzed by
flow cytometry. As expected, E5 induced a remarkable down-Fig. 2. BPV-4 E5 ORF is transcribed at comparable levels in all P815 cells. E5 and β
with standard deviation of six independent measurements. Note that the levels of E5regulation of N*01301-containing MHC class I (Fig. 3). There
was very little surface MHC class I, with a reduction of more
than five-fold compared to control cells carrying empty vector,
and also the amount of total (surface plus intracytoplasmic)
MHC class I was less than half of that in control cells. The-actin RNAwas measured by Q-RT-PCR. The histograms represent the average
RNA are three orders of magnitude lower than those of β-actin RNA.
Fig. 4. BPV-4 E5 induces degradation of classical N*01301 MHC class I heavy
chain but not non-classical N*50001 heavy chain. (A) Steady state levels of
classical N*01301 and non-classical N*50001 heavy chain in P815 control cells
or cells expressing E5. (B) Half-life measurement of classical N*01301 and non-
classical N*50001 heavy chain in cyclohexamide-treated P815 control cells and
cells expressing E5. HC, heavy chain.
Fig. 3. BPV-4 E5 down-regulates surface and total classical N*01301 MHC class I but not non-classical N*50001 MHC class I. (A) Example of flow cytometry
profiles of surface and total classical N*01301 and non-classical N*50001 MHC class I in P815 control cells or cells expressing E5. (B) Mean forward fluorescence
with standard deviation calculated from the flow cytometry profiles of at least three independent experiments in duplicate.
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pc4E5 cells, but the results obtained with P815-N*01301-
pz4E5 cells were essentially identical (data not shown). These
results confirm that 4E5 has a drastic effect on the expression
and transport of MHC class I (Ashrafi et al., 2002; Marchetti
et al., 2006). The results also show conclusively that 4E5 is
capable of down-regulating MHC class I in the absence of
any other viral oncogene.
In contrast to what was observed with N*01301, N*50001
was not at all affected by E5 and the levels of surface or total
MHC were indistinguishable from those in control cells (Fig. 3).
Identical results were obtained with P815-N*50001-pz4E5 cells
(data not shown). Given the lack of down-regulation of
N*50001 by E5 in P815 cells, it is possible that the residual
amount of MHC class I detected in bovine cells expressing E5
(Ashrafi et al., 2002; Marchetti et al., 2002) represents non-
classical MHC class I expression.
The decrease in N*01301 expression but not in N*50001
expression was confirmed by western blotting. There was less
N*01301 expressed in P815-N*01301-pc4E5 or P815-
N*01301-pzE5 cells than in the control cells (Fig. 4A); on the
contrary, the expression of N*50001 was unchanged in P815-
N*50001-pc4E5 or P815-N*50001-pz4E5 cells, although in
control cells it was lower than that of N*01301 (Fig. 4A). It has
to be noted that mAb IL-A88 did not react with mouse MHC
class I in the parental P815 cells (Fig. 4A, middle lane), and
therefore a possible cross-reaction with bovine and mouse MHC
class I can be discounted. Additionally, mAb IL-A88 did not
react with mouse MHC class I in flow cytometry experiments
with parental P815 cells (data not shown), confirming lack of
cross-reaction.Turnover of N*01301 and N*50001 in P815-4E5 cells
To investigate the reasons for the decreased expression of
N*01301 in the cells expressing 4E5, the half life of the HC was
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cyclohexamide and by following the turnover of HC by western
blotting. In control cells, N*01301 was stable and could still be
detected after 24 h of treatment; in remarkable contrast, in the
4E5-expressing cells, N*01301 was unstable and was practi-
cally undetectable after 10 h (Fig. 4B). There was no difference
between the stability of N*50001 in control or 4E5-expressing
cells; in both cases, N*50001 HC was still detectable after 24 h
of treatment, comparable to that of N*01301 in control cells
(Fig. 4B). These results confirm the general inhibition of
classical MHC class I expression by E5, from stability of the HC
protein to the transport of the class I complex to the cell surface
(Ashrafi et al., 2002, 2005; Marchetti et al., 2002, 2006). The
results also show that E5 has no effect on the expression, half-
life and transport of non-classical N*50001-MHC class I.
Localization of classical and non-classical MHC class I in
P815-4E5 cells
In PalF-4E5 cells, E5 retains the MHC class I in the Golgi
apparatus (Marchetti et al., 2002). We wondered whether the
reduction in surface N*01301-MHC class I was also due to the
retention of residual complex in the Golgi. We performed two-
color confocal immunofluorescence in the various P815 cell
lines where MHC class I was detected with mAb IL-A88 and an
FITC-conjugated secondary antibody and the Golgi apparatus
was detected with BODIPY Ceramide Texas Red. In all control
cells, whether expressing N*01301 or N*50001, MHC was
both associated with the Golgi membranes and clearly on the
cell surface (Fig. 5). In contrast, the cellular localization of
N*01301- and N*50001-MHC class I was markedly different in
P815 cells expressing c4E5 or z4E5. Classical N*01301-MHC
class I was totally associated with Golgi membranes, and no
complex was detectable on the cell surface with this technique
(Fig. 5), whereas, in sharp contrast, N*50001-MHC was clearly
on the cell surface, in addition to the Golgi membranes (Fig. 5),
and its localization pattern was no different from the one in
control cells. Again, no reaction was observed in parental P815
cells (data not shown).
The localization of N*50001 was analyzed also in bovine
PalF control cells (transformed but without E5) and in PalF-4E5
cells (transformed and expressing E5) (Ashrafi et al., 2000;
Pennie et al., 1993). FLAG-tagged N*50001 was detected both
in the Golgi apparatus and on the cell surface in both control and
PalF-4E5 cells, while a GFP fusion form of classical HC B2705
was wholly confined to the misshapen Golgi apparatus in the
PalF-4E5 cells, but not in the control cells (data not shown), as
previously reported (Marchetti et al., 2002). The results
obtained in both P815 and PalF cells show beyond doubt that
E5 is incapable of inhibiting the transport of N*50001-MHC
complex from the Golgi compartment to the surface of the cell.
Physical interaction between E5 and HC
E5 and N*01301 HC interact physically, and we have
proposed that this interaction contributes to the down-regulation
of the HC and the retention of the complex in the Golgi(Marchetti et al., 2006). Therefore, we asked whether E5 would
complex with N*50001 HC and used in vitro co-precipitation
assays as in vitro interaction between E5 and HC is a faithful
read-out for in vivo interaction (Marchetti et al., 2006; Ashrafi
et al., in press). As before, we in vitro transcribed/translated E5,
N*01301 and N*50001 HC and precipitated the HC with mAb
IL-A88. Whereas E5 co-precipitated with N*01301 HC, it did
not do so with N*50001 HC (Fig. 6A). The lack of interaction
between E5 and N*50001 was confirmed by a competition
experiment in which unlabeled N*50001 was added to labeled
E5 and labeled N*01301. Unlabeled N*50001 failed to prevent
the interaction between E5 and N*01301 (Fig. 6A), confirming
that it cannot bind to E5.
As described above, N*50001 lacks the C-terminus
intracytoplasmic tail of classical MHC class I HC and is 19
amino acids shorter than N*01301 (Fig. 1). Given the absence
of interaction between E5 and N*50001, we wondered
whether the intracytoplasmic domain of class I HC was
responsible for binding to E5. We made a C-terminus
truncation mutant of N*01301 HC lacking the final 19
amino acid residues and performed in vitro co-IP experiments
with 4E5. This mutant co-precipitated with 4E5 (data not
shown), showing that the interaction between HC and 4E5
does not involve the C-terminus intracytoplasmic domain of
HC. Furthermore, N*01301 HC bound E5 whether tagged
with V5-His at its C-terminus, like N*50001, or not (data not
shown), demonstrating that the C-terminus epitope has no
effect on the interaction.
We corroborated the in vitro interaction between E5 and HC
in a “pull-down co-immunoprecipitation” experiment. Protein
lysates for P815 parental cells, P815-N*01301 and P815-
N*50001 cells were incubated with labeled E5 and immuno-
precipitated with mAb IL-A88. As expected, no E5 could be
precipitated from P815 control cells or P815-N*50001 cells,
while E5 co-precipitated with N*01301 HC in P815-N*01301
cells (Fig. 6B).
Taken together, the results presented above lead to the firm
conclusion that E5 does not interfere with the biosynthetic
pathway of non-classical N*50001 MHC class I.
Discussion
Viruses and classical and non-classical MHC class I
It is well-documented that many viruses evade the host
immune system by interfering with the antigen processing and
presentation pathways (Piguet, 2005). These viral mechanisms
often target MHC class I, and there are several examples of
discrimination between classical and non-classical class I.
While classical class I expression is most often down-
regulated by viral interference at one or more points in the
pathway between transcription and cell-surface expression,
expression of non-classical class I genes usually remains
normal (Cohen et al., 1999; Tomasec et al., 2000; Wang et al.,
2002). It has been proposed that this enables the virus-
infected cell to evade cytotoxic T cell responses while at the
same time sending inhibitory signals to NK cells via
Fig. 5. BPV-4 E5 induces retention of classical, but not non-classical, MHC class I in the Golgi apparatus. (A) Immunofluorescent detection of classical and non-
classical MHC class I in P815 control cells or cells expressing E5.
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relates to engagement of inhibitory NK receptors by non-
classical class I molecules (Borrego et al., 2005; Hofmeister
and Weiss, 2003).Fig. 6. BPV-4 E5 interacts with classical N*01301 heavy chain but fails to interact
translated E5 and N*01301 HC or N*50001 HC were immunoprecipitated with mAb
gel, and the dried gel exposed on a screen on a Storm 840 apparatus. Classical N*0130
with E5 (lane 5) and to compete with classical N*01301 HC for binding to E5 (lane
proteins (see input lanes) which may be due to dimers or multimers of E5 or to degrad
N*01301 HC. Protein extracts from P815, P815-N*01301 and P815-N*50001 cells w
with mAb IL-A88. E5 is precipitated from P815-N*01301 cells (lane 2) but not froNon-classical MHC class I in cattle
There is considerable evidence that N*50001 and related
alleles in cattle are encoded by a non-classical MHC class Iwith non-classical N*50001 heavy chain. (A) 35S-labeled in vitro transcribed/
IL-A88, against MHC class I heavy chain; the precipitate was run in a NuPAGE
1HC interacts with E5 (lane 3), while non-classical N*50001 HC fails to interact
9). Several additional bands are visible which derive from the translation of the
ation products of HC. (B) “Pull-down co-immunoprecipitation” between E5 and
ere incubated with 35S-labeled in vitro transcribed/translated E5 and precipitated
m P815 parental or P815-N*50001 cells (lanes 3 and 4).
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classical is based on several criteria, namely association with a
number of unrelated MHC haplotypes (at least one of this set of
alleles is present on all MHC haplotypes examined; Ellis,
unpublished data), lack of significant polymorphism, a
truncated cytoplasmic domain (8 rather than 28 amino acids),
unusual amino acid substitutions throughout, a characteristic
motif within the transmembrane domain, a large deletion in the
3′ UTR and significant differences in the 5′ upstream region in
comparison to classical class I genes. These alleles may be
widely transcribed, and there is currently no evidence to suggest
tissue-specific expression (Davies et al., 2004); Ellis, unpub-
lished data). In addition, a number of alternatively spliced
transcripts of N*50001 can be found (Ellis, unpublished data), a
characteristic seen in non-classical class I genes in other species,
most notably HLA-G (Riteau et al., 2001). N*50001 and related
alleles are transcribed at relatively low levels in peripheral blood
lymphocytes and at slightly higher levels in trophoblast tissue
during pregnancy (Davies et al., 2004), in common with some
other putative non-classical cattle MHC class I alleles.
BPV-4 E5 and MHC class I
Because there is no monoclonal antibody available which
exclusively recognizes non-classical class I molecules, to study
the relationship of BPV-4 E5 with classical and non-classical
MHC I, we separately expressed a classical, N*01301, and a
non-classical, N*50001, allele in mouse P815 cells and
subsequently introduced E5 in these cells. This proved to be a
powerful system which has confirmed that E5 down-regulates
classical MHC class I, while it does not interfere with the
biosynthetic pathway of this non-classical MHC class I.
BPV-4 E5 and classical MHC class I
As in bovine PalF cells (Marchetti et al., 2006), E5 down-
regulates classical MHC class I at more than one level.
However, in PalF cells, E5 was co-expressed with E6, E7 and
activated ras (Ashrafi et al., 2000), leaving open the possibility,
albeit remote, that down-regulation of MHC class I was due to a
functional interaction between the viral and cellular oncopro-
teins. In P815 cells, E5 profoundly inhibits classical MHC class
I in the absence of other viral or cellular oncoproteins. E5
impacts on classical MHC class I at several levels: transcription
of the HC gene, expression of protein and transport of the
complex to the cell surface (Marchetti et al., 2006). Transcrip-
tion of the bovine N*01301 HC cannot be analyzed in P815
cells: E5 inhibits transcription from the homologous promoter
of the HC gene, while in P815 cells the N*01301 HC gene is
under the control of the CMV IE promoter, which is not affected
by E5 (data not shown). In P815 cells, in addition to blocking
MHC class I in the Golgi apparatus, E5 induces the degradation
of N*01301 HC. In control cells, the half-life of the HC is
approximately 20 h, whereas in the presence of E5 its half-life is
dramatically reduced to less than 5 h. We do not yet know how
E5 induces degradation of HC. However, we have commented
before (Marchetti et al., 2006) on the similarities between E5and HIV 1 Nef, and it is interesting to note that Nef re-directs
HC to the lysosomes for degradation through the simultaneous
interaction with HC and with the adaptor protein 1 (AP-1)
complex (Roeth et al., 2004) and that inhibitors of lysosomes (in
conjunction with interferon treatment) restore the expression of
HC in PalF-4E5 cells (Marchetti et al., 2006). It is thus possible
that E5 too interacts with both HC and AP-1 inducing lysosomal
degradation of HC, but this remains to be elucidated.
BPV-4 E5 and non-classical MHC class I
In marked contrast to its inhibitory effect on classical MHC
class I, E5 does not affect the non-classical MHC class I
N*50001. This conclusion is based on numerous pieces of
evidence. N*50001 reaches the cell surface, N*50001 HC is
expressed to the same levels as in control cells and its half-life is
not affected, and crucially E5 does not interact with N*50001
HC. This last point is further corroborated by the inability of
N*50001 HC to inhibit the formation of the complex between
E5 and N*01301 HC in vitro. Moreover, the finding that the
half-life of N*50001 HC is not affected by E5 supports our
hypothesis that binding to HC is needed for HC degradation.
A major difference between classical N*01301 and non-
classical N*50001 HC is the truncation of the intracytoplasmic
domain in the latter, but the interaction with 4E5 does not take
place via this domain. This finding contrasts with the binding of
Nef to the intracytoplasmic domain of HLA-A and with the
observation that the inability of Nef to bind some non-classical
HLA resides in amino acid differences in the intracytoplasmic
domain of HLA-E and the absence of the domain in HLA-G
(Pizzato et al., 2004; Williams et al., 2002). There are several
amino acid differences throughout the extracellular domains
between classical N*01301 and non-classical N*50001 HC
(Fig. 1), but which one of these differences is responsible for the
differential interaction with E5 remains to be established.
Biological significance of the lack of down-regulation of
non-classical MHC class I by E5
The lack of significant polymorphism in the non-classical
MHC class I allele described here strongly suggests that this
complex is not involved in antigen presentation and is thus more
likely to interact with NK receptors, as has been observed for a
number of non-classical class I gene products in human and
other species. Cattle have recently been shown to have a family
of genes with homology to the human KIRs (McQueen and
Parham, 2002; Storset et al., 2003), and several other putative
NK receptors have been identified (Storset et al., 2004), but thus
far interactions between these putative NK receptors and MHC
class I molecules have not been demonstrated.
Thus, while it is possible to speculate that the lack of
interaction of E5 with N*50001 constitutes a viral mechanism
for evading NK recognition, this remains to be confirmed.
Nevertheless, down-regulation of classical MHC class I and
lack of down-regulation of non-classical MHC class I by E5
strongly suggest that the viral protein is instrumental for the
establishment of viral infection by allowing the infected cell to
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host.Materials and methods
Plasmids
N*01301 cDNA, encoding heavy chain (HC) N*01301
(formerly HD6), was cloned both in pcDNA3 (Ellis et al., 1999)
and pcDNA6-V5-His (Invitrogen, Paisley, UK). Full-length
clones of N*50001 cDNA (AY188807), encoding N*50001,
were generated by PCR from cattle PBMC cDNA. This class I
gene is very prone to alternative spicing, and the most common
splice variant was used in this study. Multiple clones were
sequenced, and a clone containing the consensus sequence was
introduced into pcDNA6-V5-His (Fig. 1).
pz4E5 and pc4E5 are plasmids carrying the ORF of BPV-4
E5 under the transcriptional control of the murine MLV LTR
or the IE promoter of HCMV respectively. These plasmids
have been described before (Ashrafi et al., 2002; Pennie et al.,
1993).
Cells
P815 cells are a mouse mastocytoma cell line (ATCC). They
are grown in suspension in RPMI 1640 supplemented with 10%
FCS. Stable transfectants expressing N*01301 were produced
by transfection of pcDNA6-V5-His N*01301 and maintained
under blasticidin selection. These cells are designed P815-
N*01301. Stable P815 transfectants expressing N*50001 were
generated as described before (Ellis et al., 1999), and positive
cells were identified using blasticidin selection, screening by
western blotting with an anti-V5 monoclonal antibody (mAb)
(Invitrogen) and flow cytometry. These cells are designated
P815-N*50001. Both P815-N*01301 and P815-N*50001 were
transfected with either pz4E5 or pc4E5, or the corresponding
empty vectors, with an Amaxa nucleofector (Amaxa GmbH)
using the kits and following the instructions supplied by the
manufacturers. Cells were selected by G418 resistance, and
stable transfectants were isolated.
Quantitative RT-PCR (Q-RT-PCR)
RNA was extracted from P815 cells using RNeasy mini Kit
(Qiagen, UK), and residual DNAwas inactivated using DNase I
treatment (Invitrogen). Q-RT-PCR for BPV-4 E5 and mouse β-
actin mRNAwas carried out using the Taqman EZ RT-PCR Kit
(Applied Biosystems, Foster City, CA). Each reaction was
performed in triplicate using 100 ng of RNA. Oligonucleotide
primers, designed using Primer Express (v 1.7, Perkin-Elmer,
Oak Brook, IL), were as follows: BPV-4 E5 F5′-TGTCT-




CAT-3′; β-actin R5′-GCCACCGATCCACACAGAGT-3′ andFAM/TAMRA probe 5′-AAGATCATTGCTCCTCCTGAGC-
GAAAG-3′.
PCR reactions were performed using an ABI prism 7700
sequencer. Standard curves were generated using 10-fold serial
dilutions of each template DNA, which were used for
quantifying the relative levels of E5 and β-actin RNA.
Flow cytometric analysis of MHC class I expression
P815-N*01301 and P815-N*50001 cells either expressing
BPV-4 E5 or carrying empty vector were grown in suspension
in T175 cm2 flasks until subconfluent. Following centrifuga-
tion, the cell pellet was washed with PBS and resuspended in
PBS/1% bovine serum albumin (PBS-B) at a concentration of
106 cells/ml. For the detection of surface MHC class I
molecules, aliquot of 106 cells was incubated for 1 h at 4 °C
with monoclonal antibody (mAb) IL-A88, specific for bovine
MHC class I (Toye et al., 1990) in PBS-B. After washing twice
with PBS, cells were incubated with 1:100 dilution of anti-
mouse IgG-FITC (Sigma, UK) for 30 min at 4 °C in the dark.
The cells were washed as above, resuspended in 500 μl PBS and
analyzed by flow cytometry. If the flow cytometry analysis was
not carried out immediately, the cells were resuspended in
500 μl of 3% paraformaldehyde in PBS and kept at 4 °C. P815
cells not expressing bovine MHC class I were used as control,
as well as cells incubated without primary antibody. For the
detection of intracellular MHC class I, the cells were
permeabilized with 0.1% saponin in PBS-B for 30 min at RT
and then incubated with primary antibody as described above.
All samples were examined in a Beckman coulter EPICS Elite
analyzer equipped with an ion argon laser with 15 mV of
excitation at 488 nm. Data were analyzed using Expo 2
software.
Localization of MHC class I in P815 cells by
immunofluorescence
An eight-well slide (Chamber Slides Lab-tek, VWR
International) was washed with alcohol, air-dried and treated
with 40 μl/well poly-L lysine hydrobromide (Sigma) for 10 min
to allow adhesion of the cells. After removal of poly-L lysine,
the slide was washed with distilled water and air-dried. P815
cells were pelleted, washed twice in PBS and resuspended in
fixing solution (5% formaldehyde in PBS containing 2%
sucrose) for 10 min. After two washes, the cells were plated in
PBS containing 1% FCS, at 1 × 102 cells/well, and left for
15 min to settle down. After removal of PBS, the cells were
treated with permeabilizing solution (0.01% Tween-20 in PBS)
for 10 min. The Golgi apparatus was visualized with 1:1000
dilution of BODIPY Ceramide Texas Red (TR) (in 2.5%
HEPES in serum-free RPMI 1640 medium) for 30 min at 4 °C.
BODIPY Ceramide specifically locates to the Golgi apparatus.
After removal of BODIPY Ceramide, cells were incubated in
2.5% HEPES in serum-free RPMI 1640 medium for 30 min at
37 °C. For detection of MHC class I, cells were first incubated
with IL-A88 antibody for 1 h at RT followed by incubation with
1:1000 dilution of anti-mouse IgG-FITC for 1 h in dark with
182 E.H. Araibi et al. / Virology 353 (2006) 174–183two washes in between. The cells were washed three times, and
the slide was mounted with a 60 mm coverslip using citifluor.
Imaging
Images were captured using a Leica TCS SP2 true confocal
scanner microscope (Leica Microsystems, Heidelberg, Ger-
many) at a wavelength of 488 nm (MHC class I: FITC) or
543 nm (Golgi apparatus: Texas Red). The merge between the
fluorescent signals was achieved using the accompanying
software.
Immunoblotting
P815 cells were lysed in 300 μl of lysis buffer (0.5% NP40,
50 mM Tris pH 7.8, 150 mM NaCl) containing a protease
inhibitor cocktail (Roche, Lewes, UK). Following incubation
on ice for 30 min, the cell debris was eliminated by
centrifugation and the protein concentration was measured
using the BCA/CuSO4 assay. To determine the stability of
classical and non-classical bovine MHC class I heavy chain in
P815 cells, aliquots of 2 × 106 cells were treated with 100 μg/ml
cyclohexamide (Sigma) or the solvent DMSO (Sigma) for
different periods of time at 37 °C. The cells were washed with
ice-cold PBS, pelleted and resuspended in 100 μl of lysis buffer
as described above.
The protein samples were mixed with 4× NuPAGE SDS
sample buffer (40% Glycerol, 500 mM Tris–HCl (pH 6.8), 8%
SDS, 0.075% Serva blue G250, 0.025% phenol red) and 10×
NuPAGE Reducing Agent (0.5 M DTT). The samples were
heated at 70 °C for 10 min before loading in NuPAGE 4–12%
Bis–Tris–HCl (pH 6.4) polyacrylamide gels (Invitrogen Ltd).
Electrophoresis was performed in MES SDS Running buffer
(Invitrogen Ltd) at a constant voltage of 200 V for 60 min.
Separated protein samples were transferred to nitrocellulose
membranes by wet electrophoretic transfer using a Xcell II
blotting apparatus (Invitrogen Ltd) as per manufacturer's
instructions. The blotting was performed at a constant voltage
of 30 V for 80 min in 1× NuPAGE transfer buffer containing
10% methanol. Transfer was checked by staining the nitrocel-
lulose membrane with Ponceau S solution (Sigma).
Membranes were blocked in 5% milk in Tris-buffered saline
(TBS) containing 0.05% Tween 20 (T-TBS) for 1 h at RT or
overnight at 4 °C. For detection of MHC class I, the membranes
were incubated with mAb IL-A88 in 5% milk in T-TBS for 2 h
at RT. After two washes in T-TBS, the membranes were
incubated with 1:5000 dilution of horseradish-peroxidase-
linked sheep anti-mouse IgG whole antibody (Amersham
Biosciences) in 5% milk in T-TBS for 1 h at RT. Bound
antibody was detected by incubating the membrane for 5 min at
RT with ECL plus western blotting detection system (Amer-
sham Biosciences) according to the manufacturer's instructions.
After exposure, bound antibody was removed from the
membranes with stripping buffer (100 mM 2-Mercaptoethanol,
2% SDS, 62.5 mM Tris–HCl pH 6.7) at 50 °C for 30 min. After
washing in T-TBS, the membranes were blocked in 5% milk in
T-TBS for 1 h at RT prior to re-probing with 1:20,000 dilutionof anti-actin antibody (mAb Ab-1; CALBIOCHEM). After
incubation with mAb Ab-1, the membranes were washed two
times in T-TBS and incubated with anti-mouse IgG linked to
horseradish peroxidase as described above.
Co-immunoprecipitation
In vitro transcription/translation and co-immunoprecipitation
In vitro transcription/translation reactions were performed
using the TNT T7 Quick Coupled Transcription/Translation
System (Promega, UK) in the presence of Redivue L-[35S]
Methionine (Amersham Pharmacia Biotech, UK) following
the manufacturer's instructions. Briefly, 1 μg of pc4E5,
pcDNA3-N*01301 or pcDNA6-V5-His-N*01301, or pcDNA6-
V5-His-N*50001 was mixed in a 50 μl reaction containing
TNT mix (TNT lysate with energy generating system, T7
RNA polymerase, nucleotides, salts, recombinant RNasin
ribonuclease inhibitors) in the presence of canine microsomal
membranes (CMM) (Promega, UK) at 30 °C for 1.5 h. Half
of each transcription/translation reaction product was immu-
noprecipitated with either 10 μl rabbit antiserum Ab 274,
raised against the C-terminus of the BPV-4 E5 protein
(Anderson et al., 1997; Pennie et al., 1993) or with 3 μl mAb
IL-A88. The other half of each reaction was left without
antibody as a negative control. For co-immunoprecipitation
experiments, the individual transcription/translation products
were mixed in equivalent amounts and immunoprecipitated
with double the amount of either antibody. For competition
experiments, no [35S] Methionine was added to the reaction
containing pcDNA3-N*50001 and the unlabeled N*50001
was added to labeled E5 for an hour before the addition
of labeled N*01301 as above. After incubation overnight at
4 °C, protein G–sepharose bead suspension (Sigma) was added
for 1 h at 4 °C. Following two washes in a high salt buffer
(50 mM Tris–HCl pH 7.5, 500 mM NaCl, 1% NonidetP-40,
0.05% NaDoc) and one wash in a low salt buffer (50 mM
Tris–HCl pH 7.5, 1% NonidetP-40, 0.05% NaDoc), the
sepharose beads were resuspended in 20 μl of SDS loading
buffer, heated at 75 °C for 10 min, and then were
electrophoresed in 4–12% NuPAGE gels (Invitrogen). Gels
were fixed with glacial acetic acid and methanol, incubated for
15 min in Amplify Fluorographic reagent (Amersham, UK),
dried and exposed for autoradiography at −70 °C overnight or
exposed on a screen for quantification on a Storm 840 apparatus
using a ImageQuant v5.2 software.
Pull-down co-immunoprecipitation
Protein lysates were obtained from P815, P815-N*01301
and P815-N*50001 cells. Cells were lysed in RIPA buffer
containing a cocktail of protease inhibitors (Roche, Lewes,
UK). Protein lysates (100 μg) were incubated with in vitro
35S-labeled E5 overnight at 4 °C and immunoprecipitated with
mAb IL-A88 as described above. Immunoprecipitates were
electrophoresed in 4–12% NuPAGE gels (Invitrogen). Gels
were fixed with glacial acetic acid and methanol, incubated for
15 min in Amplify Fluorographic reagent (Amersham, UK),
dried and exposed for autoradiography at −70 °C overnight.
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